1st Dec 2009 07:00
For Immediate Release
GW Pharmaceuticals Plc
("GW Pharmaceuticals" or "the Company")
Appointment of Piper Jaffray as Nominated Advisor & Broker
Porton Down, UK, 1 December 2009 - GW Pharmaceuticals plc (AIM: GWP) is pleased to announce the appointment, with immediate effect, of Piper Jaffray Ltd as Nominated Advisor and broker to the Company.
For further information please contact:
|
GW Pharmaceuticals plc |
+ 44 (0) 20 7831 3113 |
|
Dr. Geoffrey Guy, Executive Chairman Justin Gover, Managing Director |
|
|
Piper Jaffray Ltd |
+44 (0)20 3142 8700 |
|
Neil Mackison / Rupert Winckler |
|
|
Financial Dynamics |
+ 44 (0) 20 7831 3113 |
|
Ben Atwell / John Dineen |
Notes to Editors:
About GW Pharmaceuticals
GW Pharmaceuticals was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For more information, visit www.gwpharm.com
Related Shares:
GWP.L